Patient-reported outcomes (PROs) of cemiplimab (CEMI) versus platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%: A focus on EMPOWER-Lung 1 (NCT03088540) age subgroups. (October 2022) - Gogishvili, M.; Kilickap, S.; Sezer, A.; Gümüş, M.; Bondarenko, I.; Özgüroğlu, M.; He, X.; Gullo, G.; Rietschel, P.; Quek, R.G.W.